BPC-157 + TB-500 + Cartalax - Deadpool

1 Identity

Fixed-ratio three-component article: two synthetic linear peptides plus a synthetic tripeptide bioregulator, co-lyophilized. A formulation, not a substance. Cartalax is the Khavinson-class tripeptide H-Ala-Glu-Asp-OH; it is a separate record and its identity lives there.

Contains BPC-157 + TB-500 + Cartalax

Sequence

Per component, cross-referenced. BPC-157: GEPPPGKPADDAGLV, free acid. Full-length thymosin beta-4: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH, Met6 the single oxidation-labile residue, Phe12 the only aromatic residue in the article. Cartalax: H-Ala-Glu-Asp-OH, three residues, all L, three carboxyl functions against a single basic center, so the tripeptide is strongly acidic and is supplied as the acetate or the trifluoroacetate of that one amine.

Molecular formula

Per component. BPC-157 C62H98N16O22. Thymosin beta-4 C212H350N56O78S. Cartalax C12H19N3O8 as the free acid. No combined formula is written; a mixture has none. Total nominal fill is stated alongside the per-component fills and never in place of them.

Average mass

Per component: BPC-157 1,419.556 Da; thymosin beta-4 4,963.506 Da; Cartalax 333.297 Da. At an observed 10 plus 10 plus 10 mg presentation, total nominal fill 30 mg: 7.044, 2.015 and 30.003 micromol respectively — a 3.50 : 1.00 : 14.89 molar ratio out of a 1 : 1 : 1 mass ratio. Cartalax is the molar-dominant component at equal mass, by roughly fifteen to one over the thymosin, and that is the fact that makes the per-component deconvolution work.

Monoisotopic mass

Per component: BPC-157 1,418.7042 neutral, [M+H]+ 1,419.7115; thymosin beta-4 4,960.48632 neutral, read from a deconvoluted charge envelope; Cartalax 333.1172 neutral, [M+H]+ 334.1245, [M-H]- 332.1099, [M+Na]+ 356.1064. Negative mode is the sensible primary for the Cartalax component, which carries three carboxylates.

Salt / variant note

(1) the thymosin fork: 43-mer at 4,963.506 Da against the Tb4(17-23) heptapeptide at 889.018 Da under one market name. Substituting the fragment breaks the deconvolution outright, because the heptapeptide carries no alanine and no aspartate and the residual-alanine route for Cartalax loses its subtrahend. (2) the cartalax permutation problem: AED, ADE, EAD, EDA, DAE and DEA all share formula C12H19N3O8 and are isobaric to every decimal place, so accurate mass alone cannot establish which tripeptide is present, and LC-MS/MS b and y ion sequencing is required on first lots. (3) The neighboring tetrapeptide Epitalon, AEDG at 390.349 Da, differs by a single glycine and appears in another blend in this set. (4) ratio: no standard presentation exists.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P1 — panel definitionfor all three components, run per component and never once on the vial. No metal, no lipid, no D-residue, no non-proteinogenic residue. If a thymosin lot is supplied as recombinant material the article moves to P4 in full. The marker residues are derived for this exact composition rather than assumed: aspartate is not a marker for BPC-157 here, because the 43-mer carries aspartate at positions 2, 5 and 13 and Cartalax's C-terminal residue is aspartate as well. What holds is valine for BPC-157 and threonine for thymosin beta-4, and nothing at all for Cartalax. A component without a unique marker is named as such and quantified by a stated orthogonal method rather than by assumption, so quantitative LC-MS against a Cartalax reference standard is the primary route for that component, with the residual-alanine solve stated with its conditioning figures rather than asserted to work

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Literature exists for each component, is graded and cited on that component's record and is cross-referenced from here; none of it is literature about this mixture. No published study of this fixed three-component combination has been identified, which is a statement about the search. The Cartalax component's identity rests on reagent-catalog attribution until the manufacturer confirms residue order in writing, and that qualification travels with this record.

4 Storage & specification

Storage

Co-lyophilized solid at -20 degrees C plus or minus 5 degrees C, desiccated with in-pack desiccant, protected from light, nitrogen headspace re-blanketed after any subdivision, sealed vial equilibrated to room temperature before opening. The condition is the most restrictive of the three components' conditions, taken as a single specification for the article. The nitrogen blanket is driven by Met6 in the thymosin component alone; neither BPC-157 nor Cartalax carries an oxidation-labile residue. Equilibration before opening matters more than usual because the Cartalax component is a 333 Da solid on which condensed moisture is a large proportional insult. 2-8 degrees C is acceptable for transit and for working stock held no longer than 30 days.

Shelf life

Provisional 24 months at -20 degrees C plus or minus 5 degrees C, taken as the shortest of the three component intervals and set on this company's own data rather than inherited from the component studies. The blend runs its own protocol at 0, 3, 6, 9, 12, 18 and 24 months with a parallel accelerated arm, trending per-component content, the measured ratio, methionine sulfoxide, water content, counter-ion and any new peak above 0.10 percent. No component carries a disulfide, a tryptophan or an aspartyl-glycine motif, so scrambling and that particular hydrolysis pathway are not attributes trended here.